Transapical TAVI using the JenaValve prosthesis in high-risk patients with severe aortic stenosis achieved an 88% early safety rate at 30 days and a 4% 30-day mortality rate.
Cohort (n=24)
No
Does transapical TAVI with the JenaValve prosthesis provide adequate procedural success and safety in patients requiring aortic valve replacement?
Transapical TAVI with the JenaValve prosthesis demonstrated high procedural success and improved hemodynamics, though 6-month mortality was notable in this early experience cohort.
AIMS: Since the introduction of transcatheter aortic valve implantation (TAVI), newer generation and novel devices such as the retrievable JenaValve™ have been developed. We evaluated the procedural and 6-month results of our first experience with implantation of the JenaValve™. METHODS AND RESULTS: From June 2012 to December 2013, 24 consecutive patients (mean age 80 ± 7 years, 42 % male) underwent an elective transapical TAVI with the JenaValve™. Device success was 88 %. The mortality rate was 4 % at 30 days and 31 % at 6 months. TAVI reduced the mean transvalvular gradient (44.2 ± 11.1 mmHg vs. 12.3 ± 4.3 mmHg, p < 0.001) and increased the mean aortic valve area (0.8 3 ± 0.23 to 1.70 ± 0.44 cm(2)). A mild paravalvular leakage (PVL) occurred in 4 patients (18 %) and a moderate PVL in 1 patient (4 %). Mean New York Heart Association Functional Class improved from 2.9 ± 0.5 to 2.0 ± 0.8 at 30 days. CONCLUSION: TAVI using the JenaValve™ prosthesis seems adequate and safe in this first experience cohort.
Nijenhuis et al. (Fri,) conducted a cohort in Severe symptomatic aortic stenosis (n=24). JenaValve transapical transcatheter aortic valve implantation was evaluated on Early safety at 30 days (composite of freedom from all-cause mortality, stroke, life-threatening bleeding, acute kidney injury, coronary artery obstruction, major vascular complication, and device-related valvular dysfunction) (95% CI 70-96). Transapical TAVI using the JenaValve prosthesis in high-risk patients with severe aortic stenosis achieved an 88% early safety rate at 30 days and a 4% 30-day mortality rate.